TNSN06300A1 - Derives d'imidazole pour le traitement de troubles neurodegeneratifs - Google Patents

Derives d'imidazole pour le traitement de troubles neurodegeneratifs

Info

Publication number
TNSN06300A1
TNSN06300A1 TNP2006000300A TNSN06300A TNSN06300A1 TN SN06300 A1 TNSN06300 A1 TN SN06300A1 TN P2006000300 A TNP2006000300 A TN P2006000300A TN SN06300 A TNSN06300 A TN SN06300A TN SN06300 A1 TNSN06300 A1 TN SN06300A1
Authority
TN
Tunisia
Prior art keywords
formule
treatment
composés
neurodegenerative disorders
troubles
Prior art date
Application number
TNP2006000300A
Other languages
English (en)
Inventor
Karen Jean Coffman
Michael Aaron Brodney
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN06300A1 publication Critical patent/TNSN06300A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) dans laquelle R1, R2, R3, R4, R5, R6, R7 et A répondent aux définitions indiquées. Les composés de formule (I) ont une activité d'inhibition de la production du peptides Aβ. La présente invention concerne également des compositions pharmaceutiques pour le traitement de maladies et de troubles, par exemple de troubles neurodégénératifs et/ou neurologiques, par exemple de la maladie d'Alzheimer, chez un mammifère, comprenant des composés de formule (I).
TNP2006000300A 2004-03-23 2006-09-22 Derives d'imidazole pour le traitement de troubles neurodegeneratifs TNSN06300A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55562304P 2004-03-23 2004-03-23
PCT/IB2005/000659 WO2005092864A1 (fr) 2004-03-23 2005-03-11 Composes d'imidazole destines au traitement de troubles neurodegeneratifs

Publications (1)

Publication Number Publication Date
TNSN06300A1 true TNSN06300A1 (fr) 2007-12-03

Family

ID=34961257

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000300A TNSN06300A1 (fr) 2004-03-23 2006-09-22 Derives d'imidazole pour le traitement de troubles neurodegeneratifs

Country Status (43)

Country Link
US (3) US7342118B2 (fr)
EP (1) EP1730119B1 (fr)
JP (2) JP4054845B2 (fr)
KR (1) KR100814599B1 (fr)
CN (1) CN1934091B (fr)
AP (1) AP2379A (fr)
AR (1) AR049875A1 (fr)
AT (1) ATE399155T1 (fr)
AU (1) AU2005225635B2 (fr)
BR (1) BRPI0509069B8 (fr)
CA (1) CA2560580C (fr)
CR (1) CR8644A (fr)
CY (1) CY1108347T1 (fr)
DE (1) DE602005007717D1 (fr)
DK (1) DK1730119T3 (fr)
DO (1) DOP2005000040A (fr)
EA (1) EA011689B1 (fr)
EC (1) ECSP066879A (fr)
ES (1) ES2308441T3 (fr)
GE (1) GEP20084420B (fr)
GT (1) GT200500060A (fr)
HK (1) HK1099756A1 (fr)
HN (1) HN2005000115A (fr)
HR (1) HRP20080375T3 (fr)
IL (1) IL177594A0 (fr)
IS (1) IS8550A (fr)
MA (1) MA28481B1 (fr)
NL (1) NL1028598C2 (fr)
NO (1) NO338263B1 (fr)
NZ (1) NZ549331A (fr)
PA (1) PA8627201A1 (fr)
PE (1) PE20051155A1 (fr)
PL (1) PL1730119T3 (fr)
PT (1) PT1730119E (fr)
RS (1) RS50595B (fr)
SI (1) SI1730119T1 (fr)
SV (1) SV2006002055A (fr)
TN (1) TNSN06300A1 (fr)
TW (1) TWI372146B (fr)
UA (1) UA83899C2 (fr)
UY (1) UY28817A1 (fr)
WO (1) WO2005092864A1 (fr)
ZA (1) ZA200606957B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1730119T3 (pl) * 2004-03-23 2008-10-31 Pfizer Products Incorporated Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
WO2007034326A2 (fr) 2005-09-22 2007-03-29 Pfizer Products Inc. Composes imidazoles pour le traitement de troubles neurologiques
CA2636077C (fr) 2006-01-18 2012-01-03 Amgen Inc. Composes thiazole et procedes d'utilisation
DE102006048042A1 (de) * 2006-10-11 2008-04-17 Bayer Healthcare Ag Acylaminoimidazole und Acylaminothiazole
WO2009052116A1 (fr) * 2007-10-15 2009-04-23 The Salk Institute For Biological Studies Procédés de traitement de différentes maladies et affections, et composés utilisés
US20110021625A1 (en) * 2008-01-23 2011-01-27 Lead Chemical Co., Ltd. Neuronal cell death inhibitor
WO2010096371A2 (fr) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Composés hétérocycliques qui modulent le récepteur cb2
CA2751534A1 (fr) * 2009-03-03 2010-09-10 Pfizer Inc. Nouveaux phenyl imidazoles et phenyl triazoles en tant que modulateurs de la gamma secretase
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
RU2465273C2 (ru) * 2010-08-31 2012-10-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA2850707C (fr) 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application d'antagonistes du recepteur 5-ht6 dans l'attenuation des deficits cognitifs lies au syndrome de down
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
WO2015092614A1 (fr) 2013-12-20 2015-06-25 Pfizer Inc. Altérations d'activation de notch dans le cancer du sein
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
RU2741000C2 (ru) * 2015-06-22 2021-01-22 Сумитомо Дайниппон Фарма Ко., Лтд. Производное 1,4-дизамещенного имидазола
EP3323809A4 (fr) 2015-06-22 2019-01-02 Sumitomo Dainippon Pharma Co., Ltd. Dérivé d'amide hétérocyclique bicyclique
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2018201051A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
EP3615055A1 (fr) 2017-04-28 2020-03-04 Novartis AG Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
US20210196681A1 (en) * 2018-08-27 2021-07-01 Universiteit Maastricht Selective presenilin-2 gamma-secretase inhibitors
US20220332821A1 (en) 2019-06-24 2022-10-20 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
IL290428A (en) * 2019-08-09 2022-07-01 Pfizer Solid forms of (s)-2-(((s)-8,6-difluoro-4,3,2,1-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1- (Neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentamide and their uses
US10590087B1 (en) * 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
AU2020360000B2 (en) * 2019-10-02 2023-04-20 Kainos Medicine, Inc. N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
EP4149975A2 (fr) 2020-05-13 2023-03-22 Pfizer Inc. Méthodes, thérapies et utilisations pour le traitement du cancer
EP4211167A1 (fr) 2020-09-14 2023-07-19 Pfizer Inc. Procédés, thérapies et utilisations pour le traitement du cancer
EP4255409A1 (fr) 2020-12-07 2023-10-11 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
EP4008324A1 (fr) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
US20230089434A1 (en) * 2021-09-01 2023-03-23 Springworks Therapeutics, Inc. Synthesis of nirogacestat
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
WO2023079132A1 (fr) 2021-11-08 2023-05-11 Cellestia Biotech Ag Combinaisons pharmaceutiques pour le traitement du cancer
WO2023096954A1 (fr) * 2021-11-23 2023-06-01 Teva Pharmaceuticals International Gmbh Formes à l'état solide de sels de nirogacestat
EP4223292A1 (fr) 2022-02-07 2023-08-09 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
WO2023174390A1 (fr) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 Forme cristalline de dihydrobromure de nirogacestat, son procédé de préparation et son utilisation
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11872211B2 (en) 2022-05-20 2024-01-16 Springworks Therapeutics, Inc. Treatments with nirogacestat

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512A (en) * 1846-05-09 Smut-machine
US50314A (en) * 1865-10-03 Improvement in telegraph-cables
DE1236426B (de) * 1960-08-25 1967-03-09 Dolomitwerke Gmbh Verfahren zur Wasseraufbereitung
US5401851A (en) 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
JPH07101958A (ja) 1992-10-16 1995-04-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
DE10019755A1 (de) 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
EP1289526A4 (fr) 2000-05-30 2005-03-16 Merck & Co Inc Agonistes du recepteur de la melanocortine
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
JP2002059707A (ja) * 2000-08-23 2002-02-26 Bridgestone Corp 空気入りタイヤ及び空気入りタイヤの製造方法
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
AU2003237255B8 (en) 2002-06-05 2010-01-07 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
CA2501803A1 (fr) 2002-10-09 2004-04-22 Pfizer Products Inc. Composes thiazole utiles pour le traitement des maladies neurodegeneratives
CA2501799C (fr) 2002-10-09 2008-06-17 Pfizer Products Inc. Composes pyrazole pour le traitement de maladies neurodegeneratives
JP2006182648A (ja) * 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
JP2006525990A (ja) 2003-05-12 2006-11-16 ファイザー・プロダクツ・インク 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物
CA2533554A1 (fr) 2003-08-01 2005-02-10 Pfizer Products Inc. Composes heteroaryle a 6 elements pour traiter des troubles neurodegeneratifs
EP1653952A4 (fr) 2003-08-06 2007-04-04 Pfizer Prod Inc Composes d'oxazole destines au traitement de troubles neurodegenerescents
WO2005020991A1 (fr) 2003-08-21 2005-03-10 Pfizer Products, Inc. Composes pour le traitement de maladies neurodegeneratives
US7348968B2 (en) * 2003-12-02 2008-03-25 Sony Corporation Wireless force feedback input device
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
PL1730119T3 (pl) 2004-03-23 2008-10-31 Pfizer Products Incorporated Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
US7309709B2 (en) 2004-04-01 2007-12-18 Pfizer Inc. Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
US7232820B2 (en) 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US20050222227A1 (en) 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
WO2007034326A2 (fr) * 2005-09-22 2007-03-29 Pfizer Products Inc. Composes imidazoles pour le traitement de troubles neurologiques

Also Published As

Publication number Publication date
ATE399155T1 (de) 2008-07-15
JP2007291123A (ja) 2007-11-08
NL1028598A1 (nl) 2005-09-26
HN2005000115A (es) 2009-04-20
EA011689B1 (ru) 2009-04-28
US7951958B2 (en) 2011-05-31
CN1934091A (zh) 2007-03-21
ES2308441T3 (es) 2008-12-01
GT200500060A (es) 2005-10-24
JP2007530525A (ja) 2007-11-01
US7342118B2 (en) 2008-03-11
JP4054845B2 (ja) 2008-03-05
ECSP066879A (es) 2006-11-24
CN1934091B (zh) 2012-02-08
NZ549331A (en) 2010-08-27
NO20064726L (no) 2006-12-22
MA28481B1 (fr) 2007-03-01
PE20051155A1 (es) 2006-01-28
BRPI0509069A (pt) 2007-08-21
AU2005225635A1 (en) 2005-10-06
NL1028598C2 (nl) 2006-01-03
PA8627201A1 (es) 2005-12-23
DE602005007717D1 (de) 2008-08-07
IL177594A0 (en) 2006-12-10
SV2006002055A (es) 2006-05-09
CA2560580C (fr) 2008-12-23
US7795447B2 (en) 2010-09-14
AP2006003727A0 (en) 2006-10-31
US20100168107A1 (en) 2010-07-01
PL1730119T3 (pl) 2008-10-31
RS50595B (sr) 2010-05-07
GEP20084420B (en) 2008-07-10
DOP2005000040A (es) 2005-10-21
BRPI0509069B1 (pt) 2019-07-02
SI1730119T1 (sl) 2008-10-31
UA83899C2 (uk) 2008-08-26
US20080227781A1 (en) 2008-09-18
US20050215610A1 (en) 2005-09-29
CR8644A (es) 2006-11-01
CY1108347T1 (el) 2014-02-12
EA200601494A1 (ru) 2007-02-27
CA2560580A1 (fr) 2005-10-06
KR20060123651A (ko) 2006-12-01
IS8550A (is) 2006-10-09
TW200539875A (en) 2005-12-16
AR049875A1 (es) 2006-09-13
EP1730119A1 (fr) 2006-12-13
DK1730119T3 (da) 2008-08-11
BRPI0509069B8 (pt) 2021-05-25
HK1099756A1 (en) 2007-08-24
HRP20080375T3 (en) 2008-09-30
KR100814599B1 (ko) 2008-03-17
EP1730119B1 (fr) 2008-06-25
PT1730119E (pt) 2008-09-02
AU2005225635B2 (en) 2010-06-24
AP2379A (en) 2012-03-08
WO2005092864A1 (fr) 2005-10-06
UY28817A1 (es) 2005-10-31
TWI372146B (en) 2012-09-11
ZA200606957B (en) 2008-03-26
NO338263B1 (no) 2016-08-08

Similar Documents

Publication Publication Date Title
TNSN06300A1 (fr) Derives d'imidazole pour le traitement de troubles neurodegeneratifs
TNSN06314A1 (fr) Sulfonamides destines au traitement de troubles neurodegeneratifs
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
BRPI0410711A (pt) novos compostos
MA27472A1 (fr) Acetyle 2-hydroxy-1, 3 diaminoalcanes
CA2501799A1 (fr) Composes pyrazole pour le traitement de maladies neurodegeneratives
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
TNSN06188A1 (fr) Derives de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de recepteurs de chimiokines
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN08138A1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques
MA30037B1 (fr) Compositions et procedes destines au traitement des troubles du snc
MY124786A (en) Bis-arylsulfones
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren
MA30661B1 (fr) Derives de n-phenyl-prenylamine pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux.
MA28330A1 (fr) Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine
IL174726A0 (en) Transgenic animals with serious disorders related to alzheimer's disease
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines